WO2000021983A3 - Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell - Google Patents

Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell Download PDF

Info

Publication number
WO2000021983A3
WO2000021983A3 PCT/DK1999/000538 DK9900538W WO0021983A3 WO 2000021983 A3 WO2000021983 A3 WO 2000021983A3 DK 9900538 W DK9900538 W DK 9900538W WO 0021983 A3 WO0021983 A3 WO 0021983A3
Authority
WO
WIPO (PCT)
Prior art keywords
disclosed
polypeptides
tuberculosis
antigens
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK1999/000538
Other languages
French (fr)
Other versions
WO2000021983A2 (en
Inventor
Peter Andersen
Karin Weldingh
Christina Veggerby Hansen
Walter Florio
Li Mei Meng Okkels
Rikke Louise Vinther Skjoet
Ida Rosenkrands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Priority to EP99947257A priority Critical patent/EP1117683A2/en
Priority to CA002346218A priority patent/CA2346218A1/en
Priority to AU60784/99A priority patent/AU766093B2/en
Publication of WO2000021983A2 publication Critical patent/WO2000021983A2/en
Publication of WO2000021983A3 publication Critical patent/WO2000021983A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to substantially pure polypeptides, which has a sequence identity of at least 80 % to an amino acid sequence disclosed, or which is a subsequence of at least 6 amino acids thereof, preferably a B- or T-cell epitope of the polypeptides disclosed. The polypeptide or the subsequence thereof has at least one of nine properties. The use of the disclosed polypeptides in medicine is disclosed, preferably as vaccine or diagnostic agents relating to virulent Mycobacterium. The invention further relates to the nucleotide sequences disclosed and the nucleotide sequences encoding the disclosed polypeptides. Medical and non-medical use of the nucleotide sequences is disclosed.
PCT/DK1999/000538 1998-10-08 1999-10-08 Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell Ceased WO2000021983A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99947257A EP1117683A2 (en) 1998-10-08 1999-10-08 Tb vaccine and diagnostic based on antigens from the m. tuberculosis cell
CA002346218A CA2346218A1 (en) 1998-10-08 1999-10-08 Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
AU60784/99A AU766093B2 (en) 1998-10-08 1999-10-08 Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199801281 1998-10-08
DKPA199801281 1998-10-08
US11667399P 1999-01-21 1999-01-21
US60/116,673 1999-01-21

Publications (2)

Publication Number Publication Date
WO2000021983A2 WO2000021983A2 (en) 2000-04-20
WO2000021983A3 true WO2000021983A3 (en) 2000-11-23

Family

ID=26065520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1999/000538 Ceased WO2000021983A2 (en) 1998-10-08 1999-10-08 Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell

Country Status (4)

Country Link
EP (1) EP1117683A2 (en)
AU (1) AU766093B2 (en)
CA (1) CA2346218A1 (en)
WO (1) WO2000021983A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0030368D0 (en) * 2000-12-13 2001-01-24 Inst Of Molecul & Cell Biology Dormancy-induced mycobacterium proteins
ES2231037B1 (en) * 2003-10-31 2005-12-16 Archivel Technologies, Sl USEFUL IMMUNOTHERAPIC AGENT FOR THE COMBINED TREATMENT OF TUBERCULOSIS IN ASSOCIATION WITH OTHER PHARMACOS.
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
US7608277B2 (en) * 2004-12-01 2009-10-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
WO2007108829A2 (en) * 2005-10-26 2007-09-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
ES2307402B1 (en) 2006-10-30 2009-09-30 Archivel Farma, S.L. PROFILACTIC VACCINE AGAINST TUBERCULOSIS.
US10370437B2 (en) 2013-08-30 2019-08-06 Longhorn Vaccines And Diagnostics, Llc Antibodies that modulate immunity to drug resistant and latent MTB infections
US10414819B2 (en) 2013-08-30 2019-09-17 Longhorn Vaccines And Diagnostics, Llc Monoclonal antibodies that modulate immunity to MTB and enhance immune clearance
WO2015031787A2 (en) * 2013-08-30 2015-03-05 Longhorn Vaccines And Diagnostics, Llc Enhancing immunity to tuberculosis
CN106248934B (en) * 2016-08-25 2018-04-06 中国疾病预防控制中心传染病预防控制所 Antigen of mycobacterium tuberculosis albumen Rv0446c and its t cell epitope peptide application
CN106248935B (en) * 2016-08-31 2018-04-06 中国疾病预防控制中心传染病预防控制所 Antigen of mycobacterium tuberculosis albumen Rv1798 and its t cell epitope peptide application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016646A2 (en) * 1996-10-11 1998-04-23 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016646A2 (en) * 1996-10-11 1998-04-23 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COLE S T: "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence", NATURE, vol. 393, 11 June 1998 (1998-06-11), pages 537 - 544, XP002900966 *
EIGIMEIER AT AL: "Use of an ordered cosmid library to deduce the genomic organization of Mycobacterium leprae", MOLECULAR MICROBIOLOGY, vol. 7, no. 2, 1993, pages 197 - 206, XP002900965 *

Also Published As

Publication number Publication date
EP1117683A2 (en) 2001-07-25
AU766093B2 (en) 2003-10-09
AU6078499A (en) 2000-05-01
CA2346218A1 (en) 2000-04-20
WO2000021983A2 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
CA2230885A1 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
CA2131729A1 (en) Helicobacter pylori proteins useful for vaccines and diagnostics
WO2000021983A3 (en) Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
WO2001062893A3 (en) Compounds and methods for diagnosis and immunotherapy of tuberculosis
ITFI920052A1 (en) PROTEIN EXTRACTED FROM HELICOBACTER PYLORI CYTOTOXIC STRAINS, GENE THAT EXPRESSES IT, USE OF PROTEIN AS VACCINE OR DIAGNOSTIC.
MY119003A (en) Bacterial antigens and vaccine compositions
IL95742A (en) Recombinant polypeptides and peptides nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
AU7319194A (en) Nucleotide and amino acid sequences of the envelope 1 gene of 51 hepatitis c virus isolates and the use of reagents derived therefrom as diagnostic reagents and vaccines
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
PT100781A (en) DNA SEQUENCES CODING OF EXTERNAL SURFACE PROTEINS, PROTEINS CONTAINING THE REFERENCED SEQUENCES, OBTAINED FROM BORRELIA BURGDORFERI, AND VACCINES CONTAINING THE REFERRED PROTEINS
NZ549873A (en) Compounds and methods for treatment and diagnosis of chlamydial infection by stimulating an immune response
IL100938A0 (en) Polypeptides and peptides,particularly recombinant polypeptides and peptides,and nucleic acids coding for the same and their use in the diagnosis of tuberculosis
BR9810907A (en) Monoclonal and polyclonal antibodies, peptide capable of generating an antibody, immunogenic agent, nucleotide sequence, pharmaceutical composition, use of at least one antibody, diagnostic kit, and process for preparing an immunogenic agent
CA2105057A1 (en) Dna sequences which code for virulence characteristics of streptococcus suis and part thereof polypeptides and antibodies derived therefrom and the use thereof for the diagnosis of and protection against infection by s. suis in mammals, including man
WO2003070187A3 (en) Fusion proteins of mycobacterium tuberculosis
WO2002040517A3 (en) M. tuberculosis chaperonin 60.1 and uses thereof
MX9606463A (en) Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections.
ES8703520A1 (en) PROCEDURE FOR PREPARING PARTICLES THAT CONTAIN AMINO ACID SEQUENCES AND THAT HAVE IMMUNOGENOUS PROPERTIES
CA2190515A1 (en) Vaccine against mycobacterial infections
DK610888D0 (en) CARDIODILATE INGREDIENT, METHOD OF PREPARING THEREOF AND ITS USE
IL93397A (en) Pancreatic islet cell antigen protein or peptides, their preparation by molecular cloning, their use in the diagnosis of insulin dependent diabetes mellitus and pharmaceutical compositions comprising said antigens
CA2344590A1 (en) Treatment of inflammatory disease
ATE121754T1 (en) VACCINE AGAINST BORDETELLA.
AU3036297A (en) Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2346218

Country of ref document: CA

Ref country code: CA

Ref document number: 2346218

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 60784/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999947257

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1999947257

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999947257

Country of ref document: EP